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Background
Pheochromocytoma and paraganglioma (PPGLs) are rare tumors
genealogically derived from neural crest cells which develop sym-
pathetic and parasympathetic nervous system. The World Health
Organization (WHO) classification defines pheochromocytoma as
the tumor arising from the adrenal medulla and extra-adrenal para-
ganglioma from extra-adrenal chromaffin tissue. Malignant PPGLs
are commonly defined as the tumor with metastatic lesion. The
incidence of PPGLs is 2 to 8 per million persons per year and malig-
nant PPGLs occur in 10% to 30% of all PPGLs cases (1, 2). The gold
standard of treatment strategy for non-malignant PPGLs is surgi-
cal resection and the 5-year survival rate is estimated at approxi-
mately 90% (3). However, around 10% of the patients with successful
surgical resection develop a recurrence and 50% of them have dis-
tant metastasis (4, 5). Once distant metastasis at initial diagnosis
or re-staging is detected, the 5-year survival rate is reduced to
40% to 50% (6-8). Although the treatment strategy for malignant
PPGLs remains to be established, some systemic treatments have
been attempted. Among the systemic treatments, chemotherapy
using cyclophosphamide, vincristine and dacarbazine called CVD
therapy and internal radiation therapy using [131I]meta- iodoben-
zylguanidine (131I -mIBG) called MIBG therapy have been attempted
so widely that meta-analyses of these treatments were reported.
The meta-analysis of CVD therapy showed that the rate of com-
plete response, partial response and stable disease on imaging
were 4%, 37% and 14%, respectively (9).
131I -mIBG is a radioactive agent with high-energy beta-ray
emission first developed by Wieland and Sisson et al. in 1979
(10). It is specifically taken up through its neuronal uptake-1 re-
ceptor to tumor cells derived from such neural crest cells as pheo-
chromocytoma, medullary thyroid cancer and neuroblastoma, which
leads to anticancer effect to these tumors. Therefore, MIBG ther-
apy has been attempted to treat such neuroendocrine tumors as
PPGLs, medullary thyroid carcinoma and neuroblastoma (11-13).
For malignant PPGLs, a meta-analysis of retrospective studies re-
ported that the response rate on imaging and in hormonal examina-
tion was 0-83% and 20-100%, respectively (14). However, no pro-
spective studies have been performed yet because of the extremely
low incidence of malignant PPGLs.
In accordance with these studies, our institutes have performed
MIBG therapy since early 21th century and 5 institutes including
us can performMIBG therapy in Japan at present. In this result, on
the Advanced Medical Care Committee sponsored by Japanese
Ministry of Health, Labour and Welfare held on November 2013, 131I -
mIBG was promoted to an anticancer drug which should be devel-
oped with high medical needs. Therefore, MIBG therapy for the
patients with PPGLs was authorized as one of the Japanese Ad-
vanced Medical Care Program B with high medical needs.
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Therefore, we aim in this study to establish the protocol of
prospective clinical trial of MIBG therapy ahead of sponsor initi-
ated clinical trial and to demonstrate the safety and the efficacy of
MIBG therapy for the patients with refractory PPGLs.
METHODS AND DESIGN
Study outline
The diagram of the study process is shown in Figure1. Patients
with refractory PPGLs are enrolled in this study. After screened in
accordance with both inclusion and exclusion criteria, the regis-
tered patients receive a fixed dose of 7,400 MBq of131I -mIBG. The
occurrence of adverse events is surveyed during 20 weeks after131I -
mIBG injection and all severe adverse events will be documented
and reported in detail. Both examination and imaging diagnosis are
performed in 12 weeks after 131I -mIBG injection for the evaluation of
therapeutic effect. The next course will be performed when neither
severe adverse reactions nor progression of disease is found in the
previous course.
Purpose
The primary objective is to evaluate the safety and the efficacy of
MIBG therapy for refractory PPGLs which have no conventional
treatments.
Study design
This study is an open- label, multi - institutional single arm clini-
cal trial, in which participating institutions include 4 specialized
centers in Japan of January 2017. Participating institutions are
listed in Appendix 1.
Ethical considerations and registration
This study is conducted in accordance with the International
Committee for Harmonization Good Clinical Practice (ICH-GCP)
guideline and the Declaration of Helsinki. The study protocol was
approved by the institutional review board of all participating institu-
tions. Informed consent will be provided for all patients before
registration. This study was registered with UMIN clinical Trials
Registry (UMIN000018497).
Endpoint
The primary endpoint of this study is dose limiting toxicity
(DLT). Toxicities will be graded according to the National Cancer
Institute Common Terminology Criteria for Adverse Events
(CTCAE) version 4.0. DLT is defined as follows ; grade4 hemato-
logical toxicity ; grade3 non-hematological toxicity except for
grade 3 nausea, vomiting, anorexia and hypertension. DLT will be
evaluated during first 12 weeks(84 days)after first mIBG injection.
The secondary endpoints are response rate by RECIST and by
scintigraphic evaluation of MIBG, overall survival, progression-
free survival, and adverse event/reaction.
Eligibility criteria
Inclusion criteria
Prior to enrollment in the study, patients must fulfill all of the
following criteria : confirmed refractory PPGLs, which includes 123I -
mIBG-avid pheochromocytoma, paraganglioma, malignant pheo-
chromocytoma, and malignant paraganglioma ; no prior history of
surgical treatment and radical external irradiation ; Age 20 years or
older ; Eastern Cooperative Oncology Group Performance Status
of 0 to 2 or Karnofsky Performance Scale80% ; independent feed-
ing, excretion and sleeping ; written informed consent ; having
adequate bone marrow, liver, renal, and respiratory function as
shown below.
i) WBC3,000/mm3.
ii) Hb9.0 g/dL
iii) Platelets100,000/mm3 without G-CSF.
iv) eGFR30 mL/min/1.73 m2.
v) AST100 IU/L.
vi) ALT100 IU/L.
vii) LDH400 IU/L.
viii) New York Heart Association (NYHA) Functional Classifica-
tion class I or below.
ix) HbA1c8.0%
x) Oxygen saturation96[%] at room air.
In this study, refractory PPGLs are defined as follows ; PPGLs with
severe local invasion at initial diagnosis, malignant PPGLs with
metastasis at initial diagnosis, PPGLs with local recurrence after
surgical resection and malignant PPGLs with metastasis after surgi-
cal resection.
Exclusion criteria
Patients will be excluded for any of the following reasons :
having malignancies of other histologies within 5 years except for
thyroid medullary carcinoma with multiple endocrine neoplasia
type 2, angioblastoma of retina with von Hippel -Lindau disease and
neurofibroma with neurofibromatosis type 1 ; having history of
tumor deterioration, CTCAE grade2 non-hematologic toxicity,
or grade3 hematologic toxicity under the condition of MIBG
therapy ; having any CTCAE grade2 toxicity ; verified hepatitis
B virus antigen or C virus antibody, or human immunodeficiency
virus antibody positivity ; having any other infections currently
treated ; episodes of severe symptoms due to uncontrollable in-
crease of catecholamines, fatal arrhythmia or asystole ; diagnosed
as uncontrollable symptomatic arrhythmia, thyroid dysfunction
(hyperthyroidism or hypothyroidism), respiratory disease, or
Figure1.
Study Procedure of this study.
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pleural effusion or ascites ; diagnosed as coronary artery disease,
amiodarone-treated arrhythmia, severe valvular disease of the
heart, aortic disease, bleeding disorder, or psychosis ; Pregnant or
lactating women, or women who were planning to become preg-
nant ; diagnosed as any diseases currently treated with adrenal
corticosteroids or immunosuppressants ; not applicable isolation
due to radiation control ; having episodes of allergic reaction to
potassium iodide ; having any symptomatic lesions currently treated
with palliative external irradiation.
Patient registration
The investigators send a patient registration form to the inde-
pendent data center at an academic research organization at
Kanazawa University Hospital. Patient registration began on Feb-
ruary 1st 2016 and is to continue until July 31th, 2017.
Treatment
A treatment protocol was planned in accordance with the Japa-
nese draft guidelines of MIBG therapy by Drafting Committee for
Guideline of Radiotherapy with 131I -MIBG, Committee for Nuclear
Oncology and Immunology, the Japanese Society of Nuclear Medi-
cine (JSNM) and referred to the procedure guidelines for 131I -
mIBG therapy by the European Association of Nuclear Medicine
(EANM) (15, 16).
After admission to an isolated radiation treatment room, the
patients are received 7,400 MBq of 131I -mIBG injection over 1
hour at day 0. If the permitted amount of radioisotope agents in
each institute is lower than 7,400 MBq, patients are received
maximal dose of permitted amount of radioisotopes. Before and
after injection, blood pressure, heart rate and the presence of any
symptoms are remarked on. The patients will be discharged from
the radiation treatment room when satisfying the release criteria
regulated by the Japanese regulation.
Prescribed, recommended or acceptable supportive treatments
Oral administration of potassium iodide should be performed for
the protection of the thyroid gland and 5-HT3 receptor antagonist,
bisphosphonates and denosumab are acceptable for coadministra-
tion.
Second or third MIBG therapy
For patients who have not experienced severe adverse reactions
or progression of disease in 24 weeks after the previous course, the
second and the third course of MIBG therapy will be performed.
Follow-up schedule
The follow-up schedule for evaluating the safety and the efficacy
is shown in Table 1. The study period will be from date of enroll-
ment to 20 weeks after 131I -mIBG injection. Data to evaluate the
safety of this study will be collected at enrollment, baseline, every day
from day 0 to day 4 and 2, 4, 6, 8, 12, 16 and 20 weeks after 131I -
mIBG injection. The efficacy of this study will also be evaluated
with the comparison between baseline and 12 weeks after 131I -
mIBG injection.
The independent committee for evaluating safety and efficacy is
instituted and would be called if unexpected severe adverse reac-
tions would occur. All severe adverse events including death of any
reasons, unexpected admission andunexpected prolonged admis-
sion shall be immediately reported to Japanese Ministry of Health,
Labour and Welfare.
Sample size
Target sample size was a total of 20 patients. Sample size was
based on precision of a one-sided 90% confidence interval (CI)
estimate of DLT rate. More specifically, in 15 evaluable patients
and 2 DLTs (13%) observed, the upper confidence bound using the
exact method would rule out a null rate of 33%. For chemotherapy
using cytotoxic agent, it is commonly considered acceptable that
DLT can occur in one third or less of patients. Therefore, the inci-
dence of the DLT would be allowed if the DLT would occur in 2 or
less patients under MIBG treatment. On account of the limited
use of radioactive drug, each of our institute can perform MIBG
therapy to less than a certain number of patients. Considering this
problem, the feasible number of treated patients was 15. Moreover,
allowing for a drop-out rate of approximately 20%, the total number
of patients for registration is determined.
Statistical analysis
The population analyzed for the primary endpoint included the
Table1. Follow-up schedule
Enrollment Treatment Observation
Clinical assessments,
testing and
investigations
Day of
enrollment
within 7 days
before treatment
Day 0
to Day 4 Day 14 Day 28 Day 42 Day 56 Day 84 Day 112 Day 140
Physical examinations + + + + + + + + + +
Electrocardiogram + +
Cardiac ultrasound + +
Blood examination
(common) + + + + + + + + +
Blood examination
(catecholamines) + +
Urinary examination + +
Computed tomography + +
123I -mIBG scintigraphy + +
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all treated patients The DLT is summarized using the rate of occur-
rence. The CI of DLT rate is calculated using exact method based
on binomial distribution.
RESULTS AND DISCUSSION
This is the first multi - institutional prospective study in Japan to
evaluate the safety and the efficacy of MIBG therapy for 123I -mIBG-
avid refractory PPGLs, along with the standardized treatment
protocol and the pre-specified follow-up schedule. Although some
therapeutic strategies against malignant PPGLs have been sug-
gested, prospective and systematic treatment protocols, let alone
randomized controlled trials, were not established because of the
extremely low incidence of PPGLs. Our study will play a significant
role as a breakthrough of this problem in improving the prognosis of
the patients with malignant PPGLs. Additionally, this study was
performed in accordance with the Japanese Advanced Medical
Care Program B ahead of sponsor initiated registration trial, which
intend to rationalize application for approval in accordance with the
Japanese Pharmaceutical and Medical Device Act.
In this study, we define the tumor satisfying these 2 conditions
above as “refractory” PPGLs and eligible for this study. Although
PPGLs with local invasion beyond surgical operation is commonly
not included in malignant PPGLs according to diagnostic criteria,
its clinical features and prognosis are considered to be similar to
malignant PPGLs owing to incapability of curative treatment.
Previous retrospective studies revealed that the incidence of
grade 3 or higher adverse reactions was quite low and grade 4
hematological toxicity had never occurred in the fixed dose of 7,400
MBq of 131I -mIBG (13, 17-22). However no prospective study for
the evaluation of adverse reactions has been reported and there-
fore it is considered to be needed in order to demonstrate the
safety of MIBG therapy.
DLT is defined as follows ; grade4 hematological toxicity ;
grade3 non-hematological toxicity except for grade 3 nausea,
vomiting, anorexia and hypertension. We excluded nausea from
non-hematological toxicity. Considering the therapeutic effect to
malignant tumor, nausea was one of the common adverse reac-
tions in this therapy and therefore grade 3 nausea was concluded to
be allowed. And furthermore, grade 3 of vomiting, anorexia and hy-
pertension are also defined as acceptable on account of the same
reason.
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